Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens
Stopped Study never submitted to IND. Study is being sponsored by Johnson and Johnson in the EU only.
Conditions
Interventions
- DRUG: bortezomib
- DRUG: pegylated liposomal doxorubicin
Sponsor
Millennium Pharmaceuticals, Inc.